BC Week In Review | Feb 2, 2018
Clinical News

Auris reports additional Phase III data of brimapitide for hearing loss

Auris Medical Holding AG (NASDAQ:EARS) reported additional data from the Phase III HEALOS trial evaluating single intratympanic doses of 0.4 and 0.8 mg/mL brimapitide (AM-111, D-JNKI-1, XG-102) gel in 256 patients with severe to profound...
BC Week In Review | Dec 1, 2017
Clinical News

Auris misses in Phase III hearing loss trial

Auris Medical Holding AG (NASDAQ:EARS) stock fell 49% Nov. 28 after the company said brimapitide (AM-111) missed the primary endpoint in the Phase III HEALOS trial. Neither tested dose of intratympanic brimapitide gel significantly improved...
BC Extra | Nov 28, 2017
Clinical News

Auris' lead candidate misses in Phase III hearing loss trial

Auris Medical Holding AG (NASDAQ:EARS) fell $0.40 (49%) to $0.42 Tuesday after it said brimapitide (AM-111) missed the primary endpoint in the Phase III HEALOS trial. Neither tested dose of intratympanic brimapitide gel significantly improved...
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BC Innovations | Jun 15, 2017
Tools & Techniques

Breaking the barrier

A three-way deal between Amgen Inc. , Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a small...
BioCentury | Jun 2, 2017
Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
BC Week In Review | Feb 23, 2017
Clinical News

Brimapitide: Ph II data

A double-blind, placebo-controlled, French Phase II trial in 145 patients with post-operative intraocular inflammation showed that a single 900 μg subconjunctival injection of brimapitide given at the end of ocular surgery met the primary endpoint...
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BC Innovations | Aug 18, 2016
Distillery Therapeutics

Therapeutics: c-jun N-terminal kinase (JNK); JNK1 (MAPK8)

Dermatology INDICATION: Dermatitis Mouse studies suggest that inhibiting JNK could help treat atopic dermatitis. In a mouse model of atopic dermatitis, epidermal levels of JNK were higher than in normal mice. In cultured keratinocytes from...
Items per page:
1 - 10 of 30